公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2013 | Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma | Toh H.C.; PEI-JER CHEN ; Carr B.I.; Knox J.J.; Gill S.; Ansell P.; McKeegan E.M.; Dowell B.; Pedersen M.; Qin Q.; Qian J.; Scappaticci F.A.; Ricker J.L.; Carlson D.M.; Yong W.P. | Cancer | 102 | 89 | |
2020 | Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors | Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; CHIA-CHI LIN ; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. | Molecular Cancer Therapeutics | 16 | 14 |